



# UNITED STATES PATENT AND TRADEMARK OFFICE

7

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/720,018	11/24/2003	Ritva Verho	2530-120	3149
6449	7590	05/25/2006		
ROTHWELL, FIGG, ERNST & MANBECK, P.C. 1425 K STREET, N.W. SUITE 800 WASHINGTON, DC 20005			EXAMINER ZEMAN, ROBERT A	
			ART UNIT 1645	PAPER NUMBER

DATE MAILED: 05/25/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No.

10/720,018

Applicant(s)

VERHO ET AL.

Examiner

Robert A. Zeman

Art Unit

1645

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 15 November 2005.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-32 is/are pending in the application.
- 4a) Of the above claim(s) 6-30 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-8 is/are rejected.
- 7) ☒ Claim(s) 31 and 32 is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- ☒ Notice of References Cited (PTO-892)
- ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_
- ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_
- ☐ Notice of Informal Patent Application (PTO-152)
- ☐ Other: \_\_\_\_\_

### **DETAILED ACTION**

The amendment and response filed on 11-15-2005 are acknowledged. Claims 1-8 have been amended. Claims 31-32 have been added. Claims 1-32 are pending. Claims 9-30 remain withdrawn from consideration as being drawn to non-elected inventions. Claims 1-8 and 31-32 are currently under examination.

#### ***Claim Rejections Withdrawn***

The rejection of claims 1-8 under 35 U.S.C. 112, second paragraph, as being rendered vague and indefinite by the use of the term "...characterized in that..." is withdrawn in light of the amendment thereto.

The rejection of claims 1-3 and 6-8 under 35 U.S.C. 102(a) as being anticipated by Ishikura et al. (Chemico-Biological Interactions, 2001, Vol. 130-132, pages 879-889 – IDS) is withdrawn in light of the amendment to claim 1.

The rejection of claims 1-8 under 35 U.S.C. 103(a) as being unpatentable over Ishikura et al. (Chemico-Biological Interactions, 2001, Vol. 130-132, pages 879-889 – IDS) in view of Dien et al. (Applied Biochemistry and Biotechnology, 1996, Vol. 57/58 pages 233-240 – IDS) is withdrawn in light of the amendment to claim 1.

#### ***Claim Rejections Maintained***

##### ***35 USC § 112***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Art Unit: 1645

The rejection of claims 3 and 6 under 35 U.S.C. 112, second paragraph, as being rendered vague and indefinite by the use of the term “functionally equivalent derivatives” is maintained for reasons of record.

**Applicant argues:**

1. Functionally equivalent derivatives are described in the specification at paragraphs 031-032 and 049.
2. It is well known to those of skill in the art that the amino acid sequence of a particular protein can be encoded by many nucleic acid sequences due to the degeneracy of the genetic code.
3. The skilled person knows how to vary the amino acid sequence of a known protein by making conservative substitutions.

Applicant’s arguments have been fully considered and deemed non-persuasive.

As no specific functions are disclosed to be engendered with the term “functional characteristics” it is impossible to determine what functions must be maintained in order for a given protein to be considered a “functionally equivalent derivative”. Hence, it is impossible to determine the metes and bounds of the claimed invention.

The rejection of claims 4 and 5 under 35 U.S.C. 112, second paragraph, as being rendered vague and indefinite by the use of the term “fungal origin”. It is still unclear what is meant by said term. Is applicant claiming that the recited DNA molecule is isolated from a fungi (*Ambrosiozyma monospora*) or that its evolutionarily origin is a fungi? It should be noted that Applicant did not address this rejection in her response.

***New Grounds of Rejection***

***35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-4 and 6-8 are rejected under 35 U.S.C. 102(b) as being anticipated by Richard et al. (FEBS Letters, 1999, Vol. 457, pages 135-138).

Richard et al. disclose the cloning of a NADH dependent xylitol dehydrogenase (L-xylulose reductase)[see page 136]. Moreover, it is deemed, in absence of evidence to the contrary, that the NADH dependent xylitol dehydrogenase disclosed by Richard et al. constitutes a “functionally equivalent derivative” of the enzymes with the sequences recited in claims 3 and 6 (SEQ ID NO:1-2) since it has the same enzymatic activity of the instant invention. Therefore, Ishikura et al. anticipates all the limitations of the rejected claims.

***35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Art Unit: 1645

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-8 are rejected under 35 U.S.C. 103(a) as being unpatentable over Richard et al. (FEBS Letters, 1999, Vol. 457, pages 135-138). in view of Dien et al. (Applied Biochemistry and Biotechnology, 1996, Vol. 57/58 pages 233-240 – IDS).

Richard et al. disclose the cloning of a NADH dependent xylitol dehydrogenase (L-xylulose reductase)[see page 136]. Moreover, it is deemed, in absence of evidence to the contrary, that the NADH dependent xylitol dehydrogenase disclosed by Richard et al. constitutes a “functionally equivalent derivative” of the enzymes with the sequences recited in claims 3 and 6 (SEQ ID NO:1-2) since it has the same enzymatic activity of the instant invention.

Richard et al. differs from the instant invention in that they do not disclose xylitol dehydrogenase (L-xylulose reductase) *Ambrosiozyma monospora*.

Dien et al. disclose the yeast *Ambrosiozyma monospora* is capable of utilizing pentose sugars (see abstract).

It would have been obvious to one of skill in the art to utilize the methods disclosed by Ishikura et al. to identify the yeast enzymes in the pathway. To identify said enzymes the skilled

Art Unit: 1645

artisan would first separate the genetic material from the yeast (meeting the limitations of claims 1-7). Claims 1-6, as written, read on chromosomal yeast DNA. Adherence to the methodologies of Ishikura et al. would result in the identification and recombinant production of the various yeast enzymes involved in pentose metabolism. One would have been motivated to map out the pathway in the yeast disclosed by Dien et al. in order to be able to produce recombinants to economically produce ethanol from hemicellulose biomasses (see page 233 of Dien et al. with regard to the importance of hemicellulose fermentation).

### ***Conclusion***

No claim is allowed.

Claims 31-32 are objected to as being dependent on rejected claims. Said claims would be allowable if presented in independent form.

SEQ ID NO:1 and 2 are free of the art of record.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period

Art Unit: 1645

will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert A. Zeman whose telephone number is (571) 272-0866. The examiner can normally be reached on Monday- Thursday, 7am -5:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith can be reached on (571) 272-0864. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



ROBERT ZEMAN  
PATENT EXAMINER

May 23, 2006